Navigation Links
EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
Date:4/1/2009

WATERTOWN, Mass., April 1, /PRNewswire/ -- EnVivo Pharmaceuticals today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries.

EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognition enhancement in patients with Alzheimer's disease and Schizophrenia. EnVivo recently reported positive results of its clinical bio-marker study in Schizophrenia patients in which EVP-6124 showed a significant improvement in several sensory and cognition markers. These evoked response biomarkers correlate with the degree of impairment of awareness, cognition and judgment, as well as the overall clinical condition of patients with Schizophrenia. EnVivo's clinical study in Alzheimer's patients, both naive and already on acetylcholine esterase inhibitors, is ongoing.

"MTPC is one of Japan's largest and most respected pharmaceutical companies," said Kees Been, EnVivo's chief executive officer, "and we believe that its experience in CNS-related diseases in general and its commitment in Alzheimer's disease and Schizophrenia makes MTPC an ideal partner for EVP-6124 in the Japan and Asia markets. With the strength of EnVivo's clinical data and MTPC's additional financial and development resources, we hope this partnership will accelerate the availability of a new and valuable therapy to Alzheimer's and Schizophrenia patients in the MTPC territory."

Collaboration arrangements

Under the terms of the agreement, MTPC has obtained exclusive rights to develop and commercialize EnVivo's alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan, Korea, Taiwan, Indonesia and several other Asian markets. MTPC plans to initiate Phase I clinical trials within 2010. EnVivo will receive an initial license payment and is eligible for clinical and regulatory milestones, as well as several commercial milestones. EnVivo also will receive royalties on sales of EVP-6124 in the MTPC territory.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Huntington's disease, cognition and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and is being tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) for cognition in Alzheimer's disease, and several preclinical programs such as a Gamma Secretase Modulator and a PDE10 inhibitor. For more information about EnVivo, visit www.envivopharma.com.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation is a research-driven global biopharmaceutical leader based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on cardiovascular and metabolic disorders, and immune and inflammatory diseases as well as central nervous system-related disorders. In particular, MTPC strategically focuses on drug discovery in the field of diabetes including a broad range of clinical states from metabolic risks (obesity/dyslipidemia) to complications (renal dysfunction/dialysis) and stroke including the total range of disease phases such as acute phase, convalescence and maintenance. MTPC is currently developing two Phase III clinical candidates in the U.S. and EU: MCI-196 for hyperphosphatemia and MP-146 for CKD. For more information, please visit the web site at www.mt-pharma.co.jp


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mitsubishi Electric Automation Showcases Advanced Material Handling Solutions at the North American Material Handling Show (NA 08)
2. Scientists Spot Brains Free Will Center
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
10. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
11. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: